Trial Profile
Effectiveness and Handling of Spiolto Respimat in COPD Patients - Italy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Mar 2020
Price :
$35
*
At a glance
- Drugs Olodaterol/tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms OTIVACTO
- Sponsors Boehringer Ingelheim
- 21 Aug 2018 Status changed from active, no longer recruiting to completed.
- 14 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 14 May 2018 Planned End Date changed from 18 Jun 2018 to 31 Jul 2018.